CANFOUR clinical results, interview

Cantargia listed on Nasdaq Stockholm (Small Cap)

Two Nobel Prizes with utmost significance for Cantargia’s research

The new generation of cancer treatments

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system, and by blocking signals that lead to tumour growth.

Development of new antibody-based cancer treatments

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Cantargia is since September 25, 2018 listed on Nasdaq Stockholm main market (Small Cap).

(R) Cantargia presents new positive preclinical data on antibody CAN04 at major antibody conference

Cantargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference Antibody Engineering and T...

07/12/2018

(R) Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated

Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No...

15/11/2018